Odyssey bails on public listing as US IPO landscape stutters
Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
RFK Jr axes vaccine advisory committee members
The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for…
-
RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals
The US department of Health and Human Services (HHS) will look at new ways of fast-tracking approval of drugs for…
-
ADHD drugs back in the spotlight after study debunks rising prevalence
An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical…
-
‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the…
-
MHRA warns women using weight loss jabs must use effective contraception
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has warned that women using weight loss jabs must use effective…
-
Ascletis’s daily acne tablet set for China review after Phase III win
Sagimet Bioscience’s denifanstat, a one-daily pill for the treatment of acne, has succeeded in a Phase III trial, with the…
-
Roche extends SMA market lead with Evrysdi tablet approval in Europe
Roche has won approval in Europe for a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam), as…
-
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
AbbVie’s antibody drug conjugate (ADC) Temab-A (telisotuzumab adizutecan) has demonstrated promising results in a Phase I trial in patients with…
-
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
Genmab’s antibody drug conjugate (ADC) rinatabart sesutecan (Rina-S) demonstrated positive efficacy in treating patients with endometrial cancer, as investor confidence…